Different induction of LPA receptors by chemical liver carcinogens regulates cellular functions of liver epithelial WB-F344 cells
Miku Hirane
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorShuhei Ishii
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorAyaka Tomimatsu
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorKaori Fukushima
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorKaede Takahashi
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorNobuyuki Fukushima
Division of Molecular Neurobiology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorKanya Honoki
Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan
Search for more papers by this authorCorresponding Author
Toshifumi Tsujiuchi
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Correspondence to: Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan.
Search for more papers by this authorMiku Hirane
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorShuhei Ishii
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorAyaka Tomimatsu
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorKaori Fukushima
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorKaede Takahashi
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorNobuyuki Fukushima
Division of Molecular Neurobiology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Search for more papers by this authorKanya Honoki
Department of Orthopedic Surgery, Nara Medical University, Kashihara, Nara, Japan
Search for more papers by this authorCorresponding Author
Toshifumi Tsujiuchi
Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, Kowakae, Higashiosaka, Osaka, Japan
Correspondence to: Division of Molecular Oncology, Department of Life Science, Faculty of Science and Engineering, Kinki University, 3-4-1, Kowakae, Higashiosaka, Osaka 577-8502, Japan.
Search for more papers by this authorAbstract
Lysophosphatidic acid (LPA) signaling via LPA receptors (LPA1 to LPA6) mediates a variety of cellular functions, including cell motility. In the present study, we investigated the effects of LPA receptors on cell motile activity during multi-stage hepatocarcinogenesis in rat liver epithelial WB-F344 cells treated with chemical liver carcinogens. Cells were treated with a initiator (N-nitrosodiethylamine (DEN)) and three promoters (phenobarbital (PB), okadaic acid (OA) and clofibrate) every 24 h for 2 days. Cell motile activity was elevated by DEN, correlating with Lpar3 expression. PB, OA, and clofibrate elevated Lpar1 expression and inhibited cell motile activity. To evaluate the effects of long-term treatment on cell motility, cells were treated with DEN and/or PB for at least 6 months. Lpar3 expression and cell motile activity were significantly elevated by the long-term DEN treatment with or without further PB treatment. In contrast, long-term PB treatment with or without further DEN elevated Lpar1 expression and inhibited cell motility. When the synthesis of extracellular LPA was blocked by a potent ATX inhibitor S32826 before cell motility assay, the cell motility induced by DEN and PB was markedly suppressed. These results suggest that activation of the different LPA receptors may regulate the biological functions of cells treated with chemical carcinogens. © 2015 Wiley Periodicals, Inc.
REFERENCES
- 1 Aikawa S, Hashimoto T, Kano K, Aoki J. Lysophosphatidic acid as a lipid mediator with multiple biological actions. J Biochem 2015; 157: 81–89.
- 2 Lin M-E, Herr DR, Chun J. Lysophosphatidic acid (LPA) receptors: Signaling properties and disease relevance. Prostaglandins Other Lipid Mediat 2010; 91: 130–138.
- 3 Ishii I, Fukushima N, Ye X, Chun J. Lysophospholipid receptors: Signaling and biology. Annu Rev Biochem 2004; 73: 321–354.
- 4 Tsujiuchi T, Araki M, Hirane M, Dong Y, Fukushima N. Lysophosphatidic acid receptors in cancer pathobiology. Histol Histopathol 2014; 29: 313–321.
- 5 Obo Y, Yamada T, Furukawa M, et al. Frequent mutations of lysophosphatidic acid receptor-1 gene in rat liver tumors. Mutat Res 2009; 660: 47–50.
- 6 Yamada T, Furukawa M, Hotta M, et al. Mutations of lysophosphatidic acid receptor-1 gene during progression of lung tumors in rats. Biochem Biophys Res Commun 2009; 378: 424–427.
- 7 Tsujino M, Fujii M, Okabe K, Mori T, Fukushima N, Tsujiuchi T. Differential expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in human colon cancer cells. Virchows Arch 2010; 457: 669–676.
- 8 Okabe K, Hayashi M, Wakabayashi N, et al. Different expressions and DNA methylation patterns of lysophosphatidic acid receptor genes in mouse tumor cells. Pathobiology 2010; 77: 309–314.
- 9 Eichholtz T, Jalink K, farenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biocnem J 1993; 291: 677–680.
- 10 Xu Y, Gaudette DC, Boynton JD, et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1: 1223–1232.
- 11 Ridley AJ, Schwartz MA, Burridge K, et al. Cell migration: Integrating signals from front to back. Science 2003; 302: 1704–1709.
- 12 Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D. Targeting tumor cell motility as a strategy against invasion and metastasis. Trends Pharmacol Sci 2013; 34: 283–289.
- 13 Tsujiuchi T, Hirane M, Dong Y, Fukushima N. Diverse effects of LPA receptors on cell motile activities of cancer cells. J Recept Sig Transd 2014; 34: 149–153.
- 14 Hayashi M, Okabe K, Kato K, et al. Differential function of lysophosphatidic acid receptors in cell proliferation and migration of neuroblastoma cells. Cancer Lett 2012; 316: 91–96.
- 15 Yu S, Murph MM, Lu Y, et al. Lysophosphatidic acid receptors determine tumorigenicity and aggressiveness of ovarian cancer cells. J Natl Cancer Inst 2008; 100: 1630–1642.
- 16 Hayashi M, Okabe K, Yamawaki Y, et al. Loss of lysophosphatidic acid receptor-3 enhances cell migration in rat lung tumor cells. Biochem Biophys Res Commun 2011; 405: 450–454.
- 17 Okabe K, Kato K, Teranishi M, et al. Induction of lysophosphatidic acid receptor-3 by 12-O-tetradecanoylphorbol-13-acetate stimulates cell migration of rat liver cells. Cancer Lett 2011; 309: 236–242.
- 18 Inoue S, Tanabe E, Shibata A, et al. Ethionine regulates cell motile activity through LPA receptor-3 in liver epithelial WB-F344 cells. Mol Cell Biochem 2013; 383: 173–177.
- 19 Tanabe E, Shibata A, Inoue S, Kitayoshi M, Fukushima N, Tsujiuchi T. Regulation of cell motile activity through the different induction of LPA receptors by estrogens in liver epithelial WB-F344 cells. Biochem Biophys Res Commun 2012; 428: 105–109.
- 20 Farber E. The sequential analysis of liver cancer induction. Biochim Biophys Acta 1980; 605: 149–166.
- 21 Pitot HC, Sirica AE. The stage of initiation and promotion in hepatocarcinogenesis. Biochim Biophys Acta 1980; 605: 191–215.
- 22 Weisburger JH, Madison RM, Ward JM, Viguera C, Weisburger EK. Modification of diethylnitrosamine liver carcinogenesis with phenobarbitar but not woth immunosuppression. J Natl Cancer Inst 1975; 54: 1185–1188.
- 23 Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 2007; 6: 1089–1098.
- 24 Shano S, Hatanaka K, Ninose S, Moriyama R, Tsujiuchi T, Fukushima N. A Lysophosphatidic acid receptor lacking the PDZ-binding domain is constitutively active and stimulates cell proliferation. Biochim Biophys Acta 2008; 1783: 748–759.
- 25 Fukushima N, Kimura Y, Chun J. A single receptor encoded by vzg-1/lpA1/edg-2 coupled to G proteins and mediates multiple cellular responses to lysophosphatidic acid. Proc Natl Acad Sci USA 1998; 95: 6151–6156.
- 26 Ishii I, Contos JJA, Fukushima N, Chun J. Functional comparisons of the lysophosphatidic acid receotprs, LPA1/VZG-1/EGD-2, LPA2/EDG-4, and LPA3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 2000; 58: 895–902.
- 27 Sato K, Kitahara A, Satoh K, Ishikawa T, Tatematsu M, Ito N. The placental form of glutathione S-transferase as a new marker protein for preneoplasia in rat chemical hepatocarcinogenesis. Gann 1984; 75: 199–202.
- 28 Fischer DJ, Nusser N, Virag T, et al. Short-chain phosphatidates are subtype-selective antagonists of lysophosphatidic acid receptors. Mol Pharmacol 2001; 60: 776–784.
- 29 Uehata M, Ishizaki T, Satoh H, et al. Calcium sensitization of smooth muscle mediated by a Rho-assocoated protein kinase in hypertension. Nature 1997; 389: 990–994.
- 30 Smith RJ, Sam LM, Justen JM, Bundy GL, Bala GA, Bleasdale JE. Receptor-coupled signal transduction in human polymorphonuclear neutrophils: Effects of a novel inhibitor of phospholipase C-dependent processes on cell responsiveness. J Pharmacol Exp Ther 1990; 253: 688–697.
- 31 Aoki J, Inoue A, Okudaira S. Two pathway for lysophosphatidic acid production. Biochim Biophys Acta 2008; 1781: 513–518.
- 32 Pitot HC, Barsness L, Goldsworthy T, Kitagawa T. Biochemical characterisation of stages of hepatocarcinogenesis after a single dose of diethylnitrosamine. Nature 1978; 271: 456–458.
- 33 Fujiki H, Sueoka E, Suganuma M. Tumor promoters: from chemicals to inflammatory proteins. J Cancer Res Clin Oncol 2013; 139: 1603–1614.
- 34 Lee GH, Nomura K, Kitagawa T. Comparative study on diethylnitrosamine-initiated two-stage hepatocarcinogenesis in C3H, C57BL and BALB mice promoted by various hepatopromoters. Carcinogenesis 1989; 10: 2227–2230.
- 35 Okabe K, Hayashi M, Yoshida I, Nishimura K, Fukushima N, Tsujiuchi T. Distinct DNA methylation patterns of lysophosphatidic acid receptor genes during rat hepatocarcinogenesis induced by a choline-deficient L-amino acid defined diet. Arch Toxicol 2011; 85: 1303–1310.
- 36 Jansen L, Mesnil M, Koeman J, Jongen W. Tumor promoters induce inhibition of gap junctional intersellular communucation in mouse epidermal cells by affecting the localization of connexin43 ad E-cadherin. Environ Toxicol Pharmacol 1996; 15: 185–192.
- 37 Brindley DN, Lin F-T, Tigyi GJ. Role of the autotaxin-lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys Acta 2013; 1831: 74–85.
- 38 Samadi N, Bekele R, Capatos D, Venkatraman G, Sariahmetoglu M, Brindley DN. Regulation of lysophosphatidate signaling by autotaxin and lipid phosphate phosphatases with respect to tumor progression, angiogenesis, metastasis and chemo-resistance. Biochimie 2011; 93: 61–70.
- 39 Barbayianni E, Magrioti V, Moutevelis-Minakakis P, Kokotos G. Autotaxin inhibitors: A patent review. Expert Opin Ther Patents 2013; 23: 1123–1132.
- 40 Kuwata S, Ohkubo K, Yamaguchi N, et al. Extracellular lipid metabolism influences the survival of ovarian cancer cells. Biochem Biophys Res Commun 2013; 439: 280–284.
